Veil Therapeutics
PrivateCompany Overview
Veil Therapeutics is a biotechnology company developing a polymer platform that provides a novel approach to overcoming immunogenicity in biologic drug development.
Sector
Healthcare & Life Sciences
Verticals
Biotechnology, Drug Discovery, Advanced Materials
Business Model
B2B
Customer Profile
Services & Consulting
AI Layer
Non-AI
Keywords
drug deliverybiologicsstealth biologicspolymer platformimmunogenicitydrug delivery platformlipid nanoparticlesLNPpharmacokineticsprotein therapeuticsbiotech platformdrug half-life extensionbio-conjugationstealth techdrug formulation
Historical Pricing
Historical view of private secondary pricing and transaction trends.
Veil Therapeutics Comparables
Compare Veil Therapeutics with similar companies based on industry and business-model similarity.
| Company | Similarity | Market Cap |
|---|---|---|
| ZWI Therapeutics | 89% | |
| GRO Biosciences | 79% | |
| Cartesian Therapeutics | 77% | |
Veil Therapeutics Funding Rounds
Historical fundraising activity
Veil Therapeutics Investors
Notable investors and investment history
| Investor | Rounds |
|---|---|
| MedBlue Incubator | Accelerator |
Veil Therapeutics Filings
SEC and related filings with document metadata.
| Typed | Date | Amount Offered | Amount Sold | Filling | Pages | Download |
|---|---|---|---|---|---|---|
Mock Valuation | Sign Up to view | Mock Valuation | Sign Up to view | Mock Valuation | Sign Up to view | Mock Valuation |
Mock Valuation | Sign Up to view | Mock Valuation | Sign Up to view | Mock Valuation | Sign Up to view | Mock Valuation |
Mock Valuation | Sign Up to view | Mock Valuation | Sign Up to view | Mock Valuation | Sign Up to view | Mock Valuation |
Mock Valuation | Sign Up to view | Mock Valuation | Sign Up to view | Mock Valuation | Sign Up to view | Mock Valuation |
Frequently Asked Questions
Common questions about Veil Therapeutics's valuation, stock price, and market status.
Firmographic Details
HeadquartersDurham, North Carolina
Employee Range2
Year Founded2017
Last Funding—